nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—type 2 diabetes mellitus—polycystic ovary syndrome	0.916	1	CtDrD
Valsartan—CYP2C9—urine—polycystic ovary syndrome	0.00118	0.16	CbGeAlD
Valsartan—Renal impairment—Metformin—polycystic ovary syndrome	0.000989	0.0369	CcSEcCtD
Valsartan—SLCO1B3—pituitary gland—polycystic ovary syndrome	0.000862	0.117	CbGeAlD
Valsartan—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000859	0.0321	CcSEcCtD
Valsartan—Cramp muscle—Metformin—polycystic ovary syndrome	0.000847	0.0316	CcSEcCtD
Valsartan—Neutropenia—Metformin—polycystic ovary syndrome	0.00076	0.0284	CcSEcCtD
Valsartan—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000756	0.0282	CcSEcCtD
Valsartan—Infestation NOS—Metformin—polycystic ovary syndrome	0.000725	0.0271	CcSEcCtD
Valsartan—Infestation—Metformin—polycystic ovary syndrome	0.000725	0.0271	CcSEcCtD
Valsartan—SLCO1B3—vagina—polycystic ovary syndrome	0.000713	0.097	CbGeAlD
Valsartan—SLCO1B3—endocrine gland—polycystic ovary syndrome	0.000667	0.0908	CbGeAlD
Valsartan—Rhinitis—Metformin—polycystic ovary syndrome	0.000653	0.0244	CcSEcCtD
Valsartan—Hepatitis—Metformin—polycystic ovary syndrome	0.000651	0.0243	CcSEcCtD
Valsartan—AGTR1—adrenal cortex—polycystic ovary syndrome	0.000647	0.088	CbGeAlD
Valsartan—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00064	0.0239	CcSEcCtD
Valsartan—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000604	0.0226	CcSEcCtD
Valsartan—Angiopathy—Metformin—polycystic ovary syndrome	0.000591	0.022	CcSEcCtD
Valsartan—Immune system disorder—Metformin—polycystic ovary syndrome	0.000588	0.022	CcSEcCtD
Valsartan—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000587	0.0219	CcSEcCtD
Valsartan—Malnutrition—Metformin—polycystic ovary syndrome	0.000567	0.0212	CcSEcCtD
Valsartan—Flatulence—Metformin—polycystic ovary syndrome	0.000558	0.0208	CcSEcCtD
Valsartan—Dysgeusia—Metformin—polycystic ovary syndrome	0.000555	0.0207	CcSEcCtD
Valsartan—Muscle spasms—Metformin—polycystic ovary syndrome	0.000545	0.0203	CcSEcCtD
Valsartan—Vision blurred—Metformin—polycystic ovary syndrome	0.000534	0.0199	CcSEcCtD
Valsartan—AGTR1—pituitary gland—polycystic ovary syndrome	0.000523	0.0711	CbGeAlD
Valsartan—AGTR1—adipose tissue—polycystic ovary syndrome	0.000521	0.0708	CbGeAlD
Valsartan—Syncope—Metformin—polycystic ovary syndrome	0.000508	0.019	CcSEcCtD
Valsartan—Palpitations—Metformin—polycystic ovary syndrome	0.000501	0.0187	CcSEcCtD
Valsartan—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000498	0.0186	CcSEcCtD
Valsartan—Chest pain—Metformin—polycystic ovary syndrome	0.000482	0.018	CcSEcCtD
Valsartan—Myalgia—Metformin—polycystic ovary syndrome	0.000482	0.018	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000479	0.0179	CcSEcCtD
Valsartan—AGTR1—adrenal gland—polycystic ovary syndrome	0.000467	0.0635	CbGeAlD
Valsartan—Oedema—Metformin—polycystic ovary syndrome	0.000462	0.0173	CcSEcCtD
Valsartan—Infection—Metformin—polycystic ovary syndrome	0.000459	0.0172	CcSEcCtD
Valsartan—Shock—Metformin—polycystic ovary syndrome	0.000455	0.017	CcSEcCtD
Valsartan—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000454	0.0169	CcSEcCtD
Valsartan—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000453	0.0169	CcSEcCtD
Valsartan—Skin disorder—Metformin—polycystic ovary syndrome	0.000449	0.0168	CcSEcCtD
Valsartan—Anorexia—Metformin—polycystic ovary syndrome	0.000441	0.0165	CcSEcCtD
Valsartan—AGTR1—vagina—polycystic ovary syndrome	0.000433	0.0588	CbGeAlD
Valsartan—Hypotension—Metformin—polycystic ovary syndrome	0.000432	0.0161	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000421	0.0157	CcSEcCtD
Valsartan—Paraesthesia—Metformin—polycystic ovary syndrome	0.000415	0.0155	CcSEcCtD
Valsartan—Dyspnoea—Metformin—polycystic ovary syndrome	0.000412	0.0154	CcSEcCtD
Valsartan—Somnolence—Metformin—polycystic ovary syndrome	0.000411	0.0153	CcSEcCtD
Valsartan—Dyspepsia—Metformin—polycystic ovary syndrome	0.000407	0.0152	CcSEcCtD
Valsartan—AGTR1—endocrine gland—polycystic ovary syndrome	0.000405	0.0551	CbGeAlD
Valsartan—Decreased appetite—Metformin—polycystic ovary syndrome	0.000402	0.015	CcSEcCtD
Valsartan—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000399	0.0149	CcSEcCtD
Valsartan—Fatigue—Metformin—polycystic ovary syndrome	0.000399	0.0149	CcSEcCtD
Valsartan—Constipation—Metformin—polycystic ovary syndrome	0.000395	0.0148	CcSEcCtD
Valsartan—SLCO1B1—endocrine gland—polycystic ovary syndrome	0.000386	0.0525	CbGeAlD
Valsartan—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000378	0.0141	CcSEcCtD
Valsartan—Urticaria—Metformin—polycystic ovary syndrome	0.000367	0.0137	CcSEcCtD
Valsartan—Abdominal pain—Metformin—polycystic ovary syndrome	0.000366	0.0136	CcSEcCtD
Valsartan—ALB—adrenal gland—polycystic ovary syndrome	0.00036	0.049	CbGeAlD
Valsartan—Asthenia—Metformin—polycystic ovary syndrome	0.000332	0.0124	CcSEcCtD
Valsartan—Pruritus—Metformin—polycystic ovary syndrome	0.000327	0.0122	CcSEcCtD
Valsartan—Diarrhoea—Metformin—polycystic ovary syndrome	0.000316	0.0118	CcSEcCtD
Valsartan—Dizziness—Metformin—polycystic ovary syndrome	0.000306	0.0114	CcSEcCtD
Valsartan—Vomiting—Metformin—polycystic ovary syndrome	0.000294	0.011	CcSEcCtD
Valsartan—Rash—Metformin—polycystic ovary syndrome	0.000292	0.0109	CcSEcCtD
Valsartan—Dermatitis—Metformin—polycystic ovary syndrome	0.000291	0.0109	CcSEcCtD
Valsartan—Headache—Metformin—polycystic ovary syndrome	0.00029	0.0108	CcSEcCtD
Valsartan—Nausea—Metformin—polycystic ovary syndrome	0.000275	0.0103	CcSEcCtD
Valsartan—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000195	0.0265	CbGeAlD
Valsartan—SLCO1B3—Metabolism—STAR—polycystic ovary syndrome	5.47e-05	0.00109	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	5.47e-05	0.00109	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	5.41e-05	0.00108	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—polycystic ovary syndrome	5.22e-05	0.00104	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	5.22e-05	0.00104	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	5.21e-05	0.00104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PDE3B—polycystic ovary syndrome	5.13e-05	0.00102	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	5.09e-05	0.00102	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	5.09e-05	0.00102	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—SERPINE1—polycystic ovary syndrome	5.07e-05	0.00101	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PDE3B—polycystic ovary syndrome	5.07e-05	0.00101	CbGpPWpGaD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	5.01e-05	0.000998	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	5e-05	0.000997	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	4.94e-05	0.000985	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	4.94e-05	0.000985	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HMMR—polycystic ovary syndrome	4.88e-05	0.000972	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKR1C2—polycystic ovary syndrome	4.85e-05	0.000967	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TEAD2—polycystic ovary syndrome	4.85e-05	0.000967	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	4.72e-05	0.00094	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FSHR—polycystic ovary syndrome	4.67e-05	0.000932	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	4.67e-05	0.00093	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HSD3B1—polycystic ovary syndrome	4.65e-05	0.000927	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	4.6e-05	0.000917	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	4.59e-05	0.000915	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	4.59e-05	0.000915	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—POMC—polycystic ovary syndrome	4.58e-05	0.000912	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GHRL—polycystic ovary syndrome	4.54e-05	0.000906	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP19A1—polycystic ovary syndrome	4.43e-05	0.000882	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	4.39e-05	0.000876	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	4.37e-05	0.00087	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	4.36e-05	0.000869	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RACGAP1—polycystic ovary syndrome	4.34e-05	0.000865	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	4.32e-05	0.000862	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	4.28e-05	0.000852	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	4.27e-05	0.000851	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—LHB—polycystic ovary syndrome	4.24e-05	0.000846	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FST—polycystic ovary syndrome	4.17e-05	0.00083	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HSD3B2—polycystic ovary syndrome	4.15e-05	0.000827	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	4.14e-05	0.000826	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	4.13e-05	0.000824	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADRB3—polycystic ovary syndrome	4.12e-05	0.00082	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LHB—polycystic ovary syndrome	4.07e-05	0.00081	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PNPLA2—polycystic ovary syndrome	4.07e-05	0.00081	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	4.05e-05	0.000807	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	4.02e-05	0.000801	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKR1C1—polycystic ovary syndrome	4.02e-05	0.000801	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	4.01e-05	0.000799	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.97e-05	0.000792	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	3.86e-05	0.00077	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SRD5A1—polycystic ovary syndrome	3.85e-05	0.000768	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.85e-05	0.000767	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	3.84e-05	0.000766	CbGpPWpGaD
Valsartan—ALB—Metabolism—NMNAT3—polycystic ovary syndrome	3.83e-05	0.000764	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SCT—polycystic ovary syndrome	3.81e-05	0.000759	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—VEGFA—polycystic ovary syndrome	3.77e-05	0.000751	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	3.76e-05	0.00075	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—polycystic ovary syndrome	3.73e-05	0.000744	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SULT2A1—polycystic ovary syndrome	3.7e-05	0.000737	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—STAR—polycystic ovary syndrome	3.68e-05	0.000733	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	3.68e-05	0.000733	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	3.66e-05	0.000729	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.63e-05	0.000724	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.63e-05	0.000724	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—polycystic ovary syndrome	3.59e-05	0.000715	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—RRM2—polycystic ovary syndrome	3.58e-05	0.000714	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	3.57e-05	0.000712	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF18—polycystic ovary syndrome	3.57e-05	0.000712	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP1A1—polycystic ovary syndrome	3.57e-05	0.000711	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RBP4—polycystic ovary syndrome	3.54e-05	0.000706	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	3.53e-05	0.000703	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	3.52e-05	0.000701	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPCAT2—polycystic ovary syndrome	3.51e-05	0.000699	CbGpPWpGaD
Valsartan—ALB—Metabolism—SUOX—polycystic ovary syndrome	3.51e-05	0.000699	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.49e-05	0.000695	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	3.46e-05	0.00069	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—YAP1—polycystic ovary syndrome	3.45e-05	0.000688	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NAMPT—polycystic ovary syndrome	3.32e-05	0.000661	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—YAP1—polycystic ovary syndrome	3.31e-05	0.000659	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.3e-05	0.000657	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	3.28e-05	0.000654	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMMR—polycystic ovary syndrome	3.28e-05	0.000653	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP11A1—polycystic ovary syndrome	3.27e-05	0.000653	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GAB1—polycystic ovary syndrome	3.26e-05	0.00065	CbGpPWpGaD
Valsartan—ALB—Metabolism—ISYNA1—polycystic ovary syndrome	3.26e-05	0.00065	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.25e-05	0.000648	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	3.19e-05	0.000635	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	3.14e-05	0.000625	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HSD3B1—polycystic ovary syndrome	3.13e-05	0.000623	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—INSR—polycystic ovary syndrome	3.12e-05	0.000622	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKR1C3—polycystic ovary syndrome	3.09e-05	0.000616	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.09e-05	0.000616	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	3.08e-05	0.000615	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP17A1—polycystic ovary syndrome	3.04e-05	0.000607	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—polycystic ovary syndrome	3.04e-05	0.000606	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	2.99e-05	0.000597	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	2.97e-05	0.000593	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.96e-05	0.000591	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.93e-05	0.000584	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	2.93e-05	0.000583	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.92e-05	0.000581	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PGR—polycystic ovary syndrome	2.89e-05	0.000576	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	2.87e-05	0.000572	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	2.87e-05	0.000572	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LHB—polycystic ovary syndrome	2.85e-05	0.000568	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	2.83e-05	0.000565	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	2.82e-05	0.000563	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HSD3B2—polycystic ovary syndrome	2.79e-05	0.000555	CbGpPWpGaD
Valsartan—ALB—Metabolism—TEAD2—polycystic ovary syndrome	2.77e-05	0.000552	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKR1C2—polycystic ovary syndrome	2.77e-05	0.000552	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKR1C1—polycystic ovary syndrome	2.7e-05	0.000538	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PLAT—polycystic ovary syndrome	2.68e-05	0.000535	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GHRL—polycystic ovary syndrome	2.68e-05	0.000535	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	2.67e-05	0.000532	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.67e-05	0.000531	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	2.66e-05	0.00053	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAT—polycystic ovary syndrome	2.65e-05	0.000529	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TH—polycystic ovary syndrome	2.63e-05	0.000525	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.62e-05	0.000523	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	2.61e-05	0.00052	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.59e-05	0.000515	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SLC2A4—polycystic ovary syndrome	2.56e-05	0.000511	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ATF1—polycystic ovary syndrome	2.56e-05	0.00051	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IGF1—polycystic ovary syndrome	2.56e-05	0.00051	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT2—polycystic ovary syndrome	2.56e-05	0.000509	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.5e-05	0.000498	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.49e-05	0.000495	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SULT2A1—polycystic ovary syndrome	2.48e-05	0.000495	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	2.47e-05	0.000492	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	2.43e-05	0.000485	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SERPINE1—polycystic ovary syndrome	2.43e-05	0.000484	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	2.41e-05	0.000481	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP19A1—polycystic ovary syndrome	2.41e-05	0.00048	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RRM2—polycystic ovary syndrome	2.41e-05	0.000479	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NGFR—polycystic ovary syndrome	2.36e-05	0.000471	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—POMC—polycystic ovary syndrome	2.35e-05	0.000468	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRL—polycystic ovary syndrome	2.34e-05	0.000467	CbGpPWpGaD
Valsartan—ALB—Metabolism—PNPLA2—polycystic ovary syndrome	2.32e-05	0.000463	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—YAP1—polycystic ovary syndrome	2.32e-05	0.000462	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	2.31e-05	0.00046	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	2.3e-05	0.000458	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	2.27e-05	0.000452	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	2.27e-05	0.000452	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.26e-05	0.00045	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NAMPT—polycystic ovary syndrome	2.23e-05	0.000444	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.22e-05	0.000443	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.21e-05	0.000441	CbGpPWpGaD
Valsartan—ALB—Metabolism—SRD5A1—polycystic ovary syndrome	2.2e-05	0.000439	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP11A1—polycystic ovary syndrome	2.2e-05	0.000438	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.18e-05	0.000435	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.18e-05	0.000435	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GNAS—polycystic ovary syndrome	2.15e-05	0.000429	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.15e-05	0.000428	CbGpPWpGaD
Valsartan—ALB—Metabolism—STAR—polycystic ovary syndrome	2.1e-05	0.000419	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	2.1e-05	0.000419	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKR1C3—polycystic ovary syndrome	2.08e-05	0.000414	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.08e-05	0.000414	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GNAS—polycystic ovary syndrome	2.06e-05	0.000411	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NCOR1—polycystic ovary syndrome	2.05e-05	0.000408	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP17A1—polycystic ovary syndrome	2.05e-05	0.000408	CbGpPWpGaD
Valsartan—ALB—Hemostasis—GNAS—polycystic ovary syndrome	2.04e-05	0.000406	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.96e-05	0.000391	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP1A1—polycystic ovary syndrome	1.94e-05	0.000387	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.93e-05	0.000384	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	1.9e-05	0.000379	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMMR—polycystic ovary syndrome	1.87e-05	0.000373	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—polycystic ovary syndrome	1.81e-05	0.000361	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	1.8e-05	0.000359	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSD3B1—polycystic ovary syndrome	1.79e-05	0.000356	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TH—polycystic ovary syndrome	1.77e-05	0.000353	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.77e-05	0.000352	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	1.76e-05	0.000351	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC2A4—polycystic ovary syndrome	1.72e-05	0.000343	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	1.72e-05	0.000343	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.7e-05	0.000339	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.67e-05	0.000334	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	1.67e-05	0.000333	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.65e-05	0.000329	CbGpPWpGaD
Valsartan—ALB—Metabolism—LHB—polycystic ovary syndrome	1.63e-05	0.000325	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP19A1—polycystic ovary syndrome	1.62e-05	0.000323	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—polycystic ovary syndrome	1.62e-05	0.000322	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSD3B2—polycystic ovary syndrome	1.59e-05	0.000317	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKR1C1—polycystic ovary syndrome	1.54e-05	0.000307	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	1.53e-05	0.000305	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—polycystic ovary syndrome	1.47e-05	0.000293	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	1.46e-05	0.000291	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—POMC—polycystic ovary syndrome	1.45e-05	0.000289	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.45e-05	0.000288	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNAS—polycystic ovary syndrome	1.44e-05	0.000288	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.44e-05	0.000287	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—INS—polycystic ovary syndrome	1.44e-05	0.000287	CbGpPWpGaD
Valsartan—ALB—Metabolism—SULT2A1—polycystic ovary syndrome	1.42e-05	0.000283	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—POMC—polycystic ovary syndrome	1.39e-05	0.000277	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—INS—polycystic ovary syndrome	1.38e-05	0.000275	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NCOR1—polycystic ovary syndrome	1.38e-05	0.000274	CbGpPWpGaD
Valsartan—ALB—Metabolism—RRM2—polycystic ovary syndrome	1.37e-05	0.000274	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.37e-05	0.000273	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.33e-05	0.000266	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.33e-05	0.000266	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	1.33e-05	0.000266	CbGpPWpGaD
Valsartan—ALB—Metabolism—YAP1—polycystic ovary syndrome	1.32e-05	0.000264	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—polycystic ovary syndrome	1.32e-05	0.000263	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT2—polycystic ovary syndrome	1.32e-05	0.000263	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A1—polycystic ovary syndrome	1.3e-05	0.00026	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	1.3e-05	0.00026	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAMPT—polycystic ovary syndrome	1.27e-05	0.000254	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.27e-05	0.000253	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.27e-05	0.000252	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	1.26e-05	0.000252	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	1.26e-05	0.000251	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	1.25e-05	0.00025	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.25e-05	0.000249	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—polycystic ovary syndrome	1.22e-05	0.000242	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	1.19e-05	0.000237	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	1.17e-05	0.000233	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	1.16e-05	0.000231	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	1.12e-05	0.000224	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	1.08e-05	0.000216	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	1.04e-05	0.000208	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.04e-05	0.000206	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	1.03e-05	0.000205	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.02e-05	0.000204	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—polycystic ovary syndrome	1.02e-05	0.000203	CbGpPWpGaD
Valsartan—ALB—Metabolism—TH—polycystic ovary syndrome	1.01e-05	0.000202	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—polycystic ovary syndrome	9.86e-06	0.000197	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	9.84e-06	0.000196	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—POMC—polycystic ovary syndrome	9.73e-06	0.000194	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	9.72e-06	0.000194	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—INS—polycystic ovary syndrome	9.67e-06	0.000193	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	9.56e-06	0.000191	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	9.25e-06	0.000184	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.72e-06	0.000174	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	8.61e-06	0.000172	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TH—polycystic ovary syndrome	8.28e-06	0.000165	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNAS—polycystic ovary syndrome	8.25e-06	0.000165	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	8.05e-06	0.00016	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOR1—polycystic ovary syndrome	7.86e-06	0.000157	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	7.57e-06	0.000151	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	7.45e-06	0.000149	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—polycystic ovary syndrome	6.95e-06	0.000139	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	6.76e-06	0.000135	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	6.44e-06	0.000128	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	6.1e-06	0.000122	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—polycystic ovary syndrome	6.03e-06	0.00012	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	5.69e-06	0.000113	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—polycystic ovary syndrome	5.64e-06	0.000112	CbGpPWpGaD
Valsartan—ALB—Metabolism—POMC—polycystic ovary syndrome	5.56e-06	0.000111	CbGpPWpGaD
Valsartan—ALB—Metabolism—INS—polycystic ovary syndrome	5.53e-06	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	4.61e-06	9.19e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	4.55e-06	9.07e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—INS—polycystic ovary syndrome	4.52e-06	9.02e-05	CbGpPWpGaD
